Table 3.
Effects of ivabradine and digoxin/patients with sinus rhythm.
| Before mean±SD |
Ivabradine mean±SD |
P | Digoxin mean±SD |
P | DIGvsIVA P |
|
|---|---|---|---|---|---|---|
| NYHA | 3 | 2.7±0.5 | # | 2.1±0.3 | # | § |
| NB-proBNP | 735±125 | 665±121 | ° | 582±137 | # | § |
| HR | 81±3 | 77±8 | NS | 74±3 | # | § |
| 6MWT | 392±23 | 420±28 | ° | 455±28 | # | § |
| maxHR | 153±5 | 143±4 | # | 133±5 | # | § |
| LVEF | 66±5 | 65±4 | NS | 69±3 | # | § |
| E/A | 06±0.2 | 07±0.2 | ° | 0.9±0.2 | # | § |
| E/E1 | 14.1±0.3 | 13.9±0.3 | ° | 13.3±0.4 | # | § |
| LAVi | 25±2 | 23±2 | # | 20±2 | # | § |
| LVDd | 50±1 | 49±1 | * | 46±1 | # | § |
NYHA, dyspnea NYHA class; NB-proBNP, N-terminal natriuretic peptide (pg/mL); HR, heart rate (beats/min); 6MWT, 6-min walk-test (m); maxHR, maximal heart rate (beats/min); LVEF, left ventricular ejection fraction, (%); E/A, ratio of Doppler-E and -A wave; E/E1, color tissue Doppler septal E/E1 ratio, i.e. septal values combination of E’ with peak E velocity; LAVi, index of left atrium (mL/m2); LVDd, end-diastolic left ventricular dimension (mm); SD, 1 standard deviation; NS, P value baseline versus therapy, non-significant.
* P value baseline versus therapy, P<0.05;
° P value baseline versus therapy, P<0.005;
# P value baseline versus therapy , P<0.001;
§ P value within groups (ivabradine-digoxin), P<0.001.